It is ridiculous that this company is not at an equivalent MC of AXI* and CNB*. Our Sublingual tablet work is AT LEAST equivalent to AXI* chewing gum and CNB* capsules as a MMJ delivery system. They have other products in development, and so do we. The cream should beat them both to market, so we get revs before them. What is wrong with this picture?
News 
Market Data 
Discover 
